Daily programme - 10 June 2026

This interactive session explores collaboration between industry and academia, offering practical perspectives from industry experts. Each expert will deliver a 5-minute introduction, sharing their experience, role, and insights into working across sectors. A moderator will guide the discussion with follow-up questions to deepen the conversation and surface actionable takeaways. The session then opens to the audience for an open “Ask Me Anything” Q&A, encouraging questions and active participation. Designed as a fully interactive format, the session features no slides or screens, prioritizing dialogue and direct engagement.

TP53 mutations are common in AML, often as “multi-hit” types linked to complex karyotypes. Using single-cell DNA sequencing and phenotypic analysis, we examined the zygosity and clonal architecture of TP53m AML. Among eight patients, “multi-hit” TP53 anomalies appeared in blast cells but not in mature lymphoid populations. Minor TP53m heterozygous clones persisted in mature cells and at remission, with dominant “multi-hit” clones resurfacing at relapse. The combined scDNAseq and CITEseq approach highlights distinct mutation patterns, aiding therapy guidance by distinguishing pathological multi-hit mutations from clonal haematopoiesis at remission.

Room P1+2+3

Poster and Exhibition Hall

We will present tools, platforms, and customer case studies highlighting the utility of functional screening and immune profiling for target discovery and validation.

Room P1+2+3

Poster and Exhibition Hall

Understanding cancer biology through a single molecular lens often leaves critical mechanisms unresolved. Increasingly, researchers are combining complementary molecular layers to build a more comprehensive view of disease—connecting genetic, epigenetic, proteomic, and spatial signals to better understand tumor development, heterogeneity, and progression. This symposium brings together scientists applying integrated multiomic approaches to address complex biological questions in cancer research. By featuring perspectives from researchers at different stages of their scientific careers, the session highlights how connecting diverse molecular signals into a unified analytical view is driving biological discovery and translational investigation. Together, these perspectives illustrate how examining cancer biology from multiple, complementary molecular angles supports a more comprehensive understanding of cancer biology.

Roche is pioneering costimulatory bispecifics targeting 4-1BB and CD28 to maximize the efficacy of T-cell bispecifics (TCBs) and enable chemotherapy-free regimens in early-line therapy. This session explores phase 1 biomarker data from FAP-4-1BBL, CD19-4-1BBL, and CD19-CD28 trials across solid and hematologic indications. We will present evidence of a costimulatory "Signal 2" mode of action and its contribution to clinical efficacy. Furthermore, we share findings on the distinct “personalities” of each costimulator, providing a roadmap for this emerging therapeutic class.

FFPE is the most abundant clinical sample type used in cancer research. However, extracting high-quality genomic, transcriptomic, and proteomic data from FFPE remains a major challenge. This symposium explores robust and reliable sample preparation workflows that transform FFPE from a difficult specimen into a powerful resource for multi-Omics analysis. Experts will highlight AFA enabled workflows that maximize analyte recovery, preserve molecular integrity, and deliver confident results for DNA, RNA, and proteins. Discover how integrated, automation ready workflows can provide deeper insights from FFPE, thereby accelerating biomarker discovery, translational research, and precision oncology.

(open to EACR Early Career & Student Members, pre-registration required)

Spatial biology enables detailed analysis of molecular processes within native tissue architecture. Using MACSima® Imaging Cycling Staining (MICS), hundreds of proteins and dozens of RNA markers can be detected on the same section, generating high dimensional datasets that enhance cellular characterization and improve therapeutic target solutions. After an introduction into Miltenyi Biotec's innovative spatial biology and imaging solutions, we will demonstrate how B cells play a pivotal role in shaping the TME and tertiary lymphoid structures (TLS). The functions of specific B cell subsets in cancer pathogenesis remain unclear. Using a tissue-centric single-cell RNA-sequencing pipeline, flow cytometry, and high-plex spatial biology MACSima platform, we identify CD27⁻IgD⁻CD21⁺CD11c⁻ double negative 1 (DN1) B cells as a regulatory population enriched in RCC tumours and associated with worse prognosis. These cells localize within immature tertiary lymphoid structures near IL-10⁺ and TGFβ⁺ CD8⁺ T cells. TLR signalling drives their differentiation, and DN1 B cells suppress CD8⁺ T cell cytotoxicity partially via IL-10 and TGFβ. Our findings reveal a novel immune evasion mechanism with potential diagnostic and therapeutic relevance.

Biology is complex, and the mechanisms that drive biological systems are challenging to decipher. Examining any single layer of biology can provide a valuable perspective, but it reveals only part of the picture. Bruker Spatial Biology delivers best-in-class solutions designed to work together as a cohesive ecosystem. By providing high fidelity resolution and information depth across layers of biological complexity, Bruker Spatial Biology enables insights that cannot be achieved by single layer approaches, accelerating discovery through translational cancer research. Prof. Pagani will exemplify how his laboratory is using CosMx Same-Cell Multiomics to determine metastatic cell states in colorectal cancer.

Proteomics is gaining increasing attention in cancer research by providing functional insights beyond genomics and driving novel biomarker discovery. This symposium highlights how high-throughput proteomics enables a deeper understanding of tumor biology, early detection, and treatment response.

Room P1+2+3

Poster and Exhibition Hall

Discover how ATCC’s advanced human models are helping to move cancer research beyond traditional cell lines. From engineered cells to organoids, these biologically relevant systems provide more predictive and translational insights, helping researchers better capture the complexity of human tumours and accelerate progress from discovery to therapeutic development.

Spotlight Theatre

Poster and Exhibition Hall